PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

Similar documents
Ludwig Presence at 2016 ASCO Annual Meeting

Summary of Research and Writing Activities in Oncology

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

Duke at. American Society of Clinical Oncology Chicago, Illinois

Highlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer

DEPARTMENT OF ONCOLOGY ELECTIVE

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

Oncology 101. Cancer Basics

Cancer Prevention & Control in Adolescent & Young Adult Survivors

National Cancer Drugs Fund List - Approved

Curriculum: Goals and Objectives Department of Medicine Harbor-UCLA Medical Center

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

Title Cancer Drug Phase Status

American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG.

Roche Investor Relations ASCO Planner 2016

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives

Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

Online/Self study courses

2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types

Online/Self-study courses

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016

CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Precision CAR T Cell Therapeutics. Carl June October 15, 2018

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

Radiation Oncology Study Guide

Reprogramming Tumor Associated Dendritic Cells for Immunotherapy

SUPPLEMENTARY INFORMATION

Cancer Awareness Talk ICPAK 2014

ICLIO National Conference

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Annual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018

TUESDAY, 18th OCTOBER, 2016 / DAY -2

Medical Marijuana Use in Patients with History of SCCHN Treated with Radiotherapy

Development status of OPDIVO (nivolumab) 1

Radiation Oncology MOC Study Guide

Immuno-Oncology Applications

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

CSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? What does CQCO do? What is the Cancer System Quality Index?

Posters and Presentations

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Fighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program

Making a Difference. Highest quality care. Education. Research. Innovation. OUR MISSION:

NRG ONCOLOGY SEMIANNUAL MEETING PRELIMINARY AGENDA Phoenix Convention Center Phoenix, Arizona February 7 9, 2019

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017

American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG.

MEASURE SPECIFICATIONS

Emerging Targets in Immunotherapy

Quarterly Health Topics Series Sanofi s Vision in Oncology. Wednesday, June 13, 2018

MEASURE SPECIFICATIONS

:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

Development status of OPDIVO (nivolumab) 1

Indiana University Hematology Oncology Fellows Research Interest

2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL

CODING TUMOUR MORPHOLOGY. Otto Visser

QOPI and the Rapid Learning Oncology Care System. Copyright 2011 American Society of Clinical Oncology. All rights reserved 1

ASCO 2018 Summary of Presentation. May 16, 2018

Scarce Resources are best Applied to Prevention The Anti Argument

Immunotherapy: The Newest Treatment Route

UCI. Anti-Cancer Challenge Impact report. #weareanticancer

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 25-27, 2017

TUMOR M ARKERS MARKERS

Quality of End-of-Life Care in Patients with Hematologic Malignancies: A Retrospective Cohort Study

Merck ASCO 2015 Investor Briefing

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

NewLink Genetics Corporation

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths

Program Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Steamboat Springs, Colorado. January 15-18, 2016

ONCOLOGY AND MALIGNANT HEMATOLOGY REVIEW CONFERENCE

(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018

2016 Oncology Institute Annual Report

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

Current and Future Treatment Options for Glioblastoma

Identifying and counting people living with treatable but not curable cancer

Current Fellow Projects

MEDICAL ONCOLOGY Maintenance of Certification (MOC) Examination Blueprint

Your contact. Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody

Supplementary Materials for

Recent Advances in Gastrointestinal Cancers

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

CODING PRIMARY SITE. Nadya Dimitrova

Summary of Strategic Competitive Analysis and Publication Planning

The Latest in Non-Hodgkin Lymphoma News From ASCO

Managing Older Patients With Lymphoma and Multiple Myeloma

October 17 20, 2018 New York City. An International Congress on Lymphoma, Myeloma, and Leukemia Disorders

Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, Steamboat Springs, Colorado. January 12-15, 2018

Transcription:

MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments to Daily Practice Track(s): Central Nervous System Tumors; Fostering Moral Resilience: Steps You Can Take to Manage Moral Distress and Burnout in Oncology Track(s): Professional Development; Ethics Acute Myeloid Leukemia in Older Adults: More Versus Less Therapy Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant; Disparities/Health Equity; Geriatric Oncology; Management of Uncommon and Rare Breast Cancers Track(s): Breast Cancer Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges Track(s): Pediatric Oncology; Clinical Trials; Ethics; Health Services Research, Clinical Informatics, and Quality of Care The Impact of Big Data Research on Practice, Policy, and Patient Care Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Clinical Trials; Disparities/ Health Equity; Value Value-Added Decisions in Oncology: Searching High and Low Using Clinical Vignettes Track(s): Care Delivery and Practice Management; Gastrointestinal (Colorectal) Cancer; Genitourinary (Prostate) Cancer; Lung Cancer; Value Meet the Professor: Can We Cure Myeloproliferative Neoplasms? Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant; Symptoms and Survivorship Meet the Professors: Surgery, Liver-Directed Treatment, or Systematic Therapy Where Are the Boundaries for Hepatic Metastases? Developmental Therapeutics and Tumor Biology (Nonimmuno) Track(s): Developmental Therapeutics and Translational Research Genitourinary (Nonprostate) Cancer Lung Cancer Non-Small Cell Metastatic Track(s): Lung Cancer Page 1 of 6

8:00 AM - 11:00 AM S S 9:45 AM - 10:45 AM 9:45 AM - 11:00 AM S S 9:45 AM - 11:15 AM 9:45 AM - 12:45 PM S Sarcoma Track(s): Sarcoma Track(s): Gastrointestinal (Colorectal) Cancer Track(s): Gastrointestinal (Colorectal) Cancer Gastrointestinal (Noncolorectal) Cancer Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Hematologic Malignancies Plasma Cell Dyscrasia Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Managing Early Relapse in Multiple Myeloma Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal? Track(s): Central Nervous System Tumors; Navigating a New Cancer Diagnosis: Guiding Communication and Education Track(s): Pediatric Oncology; Disparities/Health Equity; Health Services Research, Clinical Informatics, and Quality of Care Clinical Controversies: Are Geriatric Syndromes in the Domain of the Oncologist? Track(s): Geriatric Oncology; Care Delivery and Practice Management; Meet the Professors: How to Write an Outstanding Manuscript Track(s): Professional Development Special Clinical Science Symposium #3 ASCO/American Association for Cancer Research (AACR) Joint Session: Conducting Histology- Agnostic Clinical Trials Breast Cancer Local/Regional/Adjuvant Track(s): Breast Cancer Cancer Prevention, Hereditary Genetics, and Epidemiology Page 2 of 6

11:30 AM - 12:15 PM AWARD LECTURE 11:30 AM - 12:30 PM S 11:30 AM - 12:45 PM S S 11:30 AM - 1:00 PM S 12:00 PM - 1:00 PM ANNUAL BUSINESS MEETING 1:15 PM - 2:00 PM Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care Track(s): Emerging New Standards of Care for Advanced Kidney Cancer ; Clinical Trials; Immunotherapy Implementing Palliative and Supportive Care in Cancer Care Worldwide Track(s): Global Health; Academic-Community Partnerships: Approaches to Engagement Track(s): Care Delivery and Practice Management; Health Services Research, Clinical Informatics, and Quality of Care Beyond Checkpoint Blockade: An Update on Engineered T-Cell Therapy and Neoantigen Vaccine Application Track(s): Developmental Immunotherapy and Tumor Immunobiology Oncology Reimbursement Reform: Are Changes on the Horizon for Promotion of Higher Value Care? Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Care Delivery and Practice Management; Value The More Things Change: Ovarian Cancer Edition Track(s): Gynecologic Cancer Meet the Professor: The Future of Immunotherapy in Non Small Cell Lung Cancer Track(s): Lung Cancer; Developmental Immunotherapy and Tumor Immunobiology; Immunotherapy Meet the Professors: Peptide Receptor Radionuclide Therapy and Systemic Treatment in Gastrointestinal Neuroendocrine Tumors Sarcoma Clinical Science Symposium Track(s): Sarcoma Gastrointestinal (Colorectal) Cancer Track(s): Gastrointestinal (Colorectal) Cancer Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia ASCO Annual Business Meeting (ASCO Members Only) AWARD LECTURE ASCO/American Cancer Society Award and Lecture Page 3 of 6

1:15 PM - 2:15 PM S 1:15 PM - 2:30 PM S S 1:15 PM - 2:45 PM Clinical Conundrums in the Management of Rectal Cancer Track(s): Gastrointestinal (Colorectal) Cancer Controversies in Breast Cancer Adjuvant Therapy Track(s): Breast Cancer; Geriatric Oncology Immunotherapies in Thymic Malignancies, Mesothelioma, and Small Cell Carcinoma Track(s): Lung Cancer; Immunotherapy International Collaborations and Regional Challenges in Sarcoma Track(s): Sarcoma; Clinical Trials; Disparities/Health Equity; Global Health The Elephant in the Room: Addressing Depression and Suicide Among Oncology Providers Track(s): Professional Development; Care Delivery and Practice Management Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients? Track(s): Developmental Immunotherapy and Tumor Immunobiology Meet the Professors: Chemotherapy, Radiation, Surgery, and Immunotherapy Optimizing Sequence and Combination of Multidisciplinary Care for Borderline Resectable Pancreatic Cancer (BRPC) Meet the Professors: Treatment Advances and Opportunities in Testicular Cancer Education Research Clinical Science Symposium Track(s): Professional Development 1:15 PM - 4:15 PM S S Hematologic Malignancies Plasma Cell Dyscrasia Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Central Nervous System Tumors Track(s): Central Nervous System Tumors Gynecologic Cancer Track(s): Gynecologic Cancer Cancer Prevention, Hereditary Genetics, and Epidemiology Genitourinary (Nonprostate) Cancer Melanoma/Skin Cancers Track(s): Melanoma/Skin Cancers Track(s): Page 4 of 6

3:00 PM - 4:00 PM S 3:00 PM - 4:15 PM Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions Track(s): Care Delivery and Practice Management; Disparities/Health Equity; Immunotherapy; Multidisciplinary Care in Challenging Sarcoma Scenarios Track(s): Sarcoma S Clinical Controversies in Relapsed Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy 3:00 PM - 4:30 PM Employing Big Data and Predictive Analytics to Determine Patient Risk in Oncology Track(s): Care Delivery and Practice Management; Health Services Research, Clinical Informatics, and Quality of Care; Value How to Measure Quality in Value-Based Systems Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Disparities/Health Equity; Value Local-Regionally Advanced Non Small Cell Lung Cancer: Advances in Multimodality Treatment Track(s): Lung Cancer; Immunotherapy Molecular Profiling in Breast Cancer: Past, Present, and Future Track(s): Breast Cancer; Cancer Prevention, Hereditary Genetics, and Epidemiology Meet the Professors: Treatment of Rare but Critical Mutations in Non Small Cell Lung Cancer Track(s): Lung Cancer; Geriatric Oncology Clinical Science Symposium Track(s): Geriatric Oncology; Disparities/Health Equity 4:30 PM - 6:00 PM S 4:45 PM - 5:30 PM Gastrointestinal (Noncolorectal) Cancer Cancer Prevention, Hereditary Genetics, and Epidemiology Genitourinary (Nonprostate) Cancer Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Melanoma/Skin Cancers Track(s): Melanoma/Skin Cancers Track(s): AWARD LECTURE B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology Track(s): Geriatric Oncology Page 5 of 6

4:45 PM - 5:45 PM S 4:45 PM - 6:00 PM S Financial Assistance for Participation in Clinical Trials: What Works Best for Patients? Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Care Delivery and Practice Management; Clinical Trials; Disparities/Health Equity Recognizing, Understanding, and Overcoming Toxicities From Immune Checkpoint Inhibitors Track(s): Developmental Immunotherapy and Tumor Immunobiology; Gastrointestinal (Noncolorectal) Cancer; Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma New Options in Metastatic Squamous Cell Carcinoma Track(s): Lung Cancer; Meet the Professors: Offering Patients With Relapsed and Refractory Follicular Lymphoma the Best Choice in a Sea of Novel Options Page 6 of 6